Related Experiment Video
Updated: May 18, 2026

Using Mouse Mammary Tumor Cells to Teach Core Biology Concepts: A Simple Lab Module
Published on: June 18, 2015
PELP1/MNAR suppression inhibits proliferation and metastasis of endometrial carcinoma cells
1Department of Gynecology and Obstetrics, The Third Affiliated Hospital, Sun Yat‑sen University, Guangzhou, Guangdong 510630, PR China.
Abstract:
Proline-, glutamic acid- and leucine-rich protein-1/modulator of non-genomic activity of estrogen receptor (ER) (PELP1/MNAR) is a novel nuclear receptor (NR) co-activator that plays an essential role in the actions of ER. Emerging findings suggest that PELP1/MNAR is a novel proto-oncogene, whose expression is deregulated in several hormone-responsive cancers, including endometrial cancer. In this study, we demonstrate that PELP1/MNAR is widely expressed in endometrial carcinoma cell lines. To investigate its possible role in endometrial carcinoma progression, we adopted an RNA interference technology to downregulate PELP1/MNAR expression in Ishikawa endometrial carcinoma cells. PELP1/MNAR downregulation substantially reduced cell proliferation, and the cells in which PELP1/MNAR expression was knocked down also exhibited a decreased migration and invasion ability, as shown by Boyden chamber and invasion assays. The results showed that the expression of MMP-2 and MMP-9 was also decreased. These results suggest that PELP1/MNAR plays a role in endometrial cancer progression and metastasis, and that PELP1/MNAR may be a potential therapeutic target for endometrial cancer.
Insights
Proline-rich protein 1 (PELP1/MNAR) drives endometrial cancer growth and metastasis. Downregulating PELP1/MNAR in cancer cells reduced proliferation and invasion, suggesting it as a therapeutic target.
Area of Science:
- Oncology
- Molecular Biology
- Endocrinology
Background:
- Proline-, glutamic acid- and leucine-rich protein-1/modulator of non-genomic activity of estrogen receptor (PELP1/MNAR) is a nuclear receptor co-activator.
- PELP1/MNAR is implicated as a proto-oncogene with deregulated expression in hormone-responsive cancers.
Purpose of the Study:
- To investigate the role of PELP1/MNAR in endometrial carcinoma progression and metastasis.
- To assess PELP1/MNAR as a potential therapeutic target for endometrial cancer.
Main Methods:
- PELP1/MNAR expression was downregulated using RNA interference in Ishikawa endometrial carcinoma cells.
- Cell proliferation, migration, and invasion assays (Boyden chamber) were performed.
- Expression levels of MMP-2 and MMP-9 were analyzed.
Main Results:
- Downregulation of PELP1/MNAR significantly reduced endometrial carcinoma cell proliferation.
- Decreased migration and invasion abilities were observed in PELP1/MNAR-knockdown cells.
- Expression of matrix metalloproteinases MMP-2 and MMP-9 was reduced.
Conclusions:
- PELP1/MNAR plays a significant role in endometrial cancer progression and metastasis.
- PELP1/MNAR is a potential therapeutic target for endometrial cancer treatment.
Related Concept Videos
Abnormal Proliferation
Mitogens and the Cell Cycle
